Document is current

Any future updates will be listed below

Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC

Crossref DOI link: https://doi.org/10.1186/s12885-024-13210-9

Published Online: 2024-11-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark